Bay Area's Pionyr Immunotherapeutics Scores $62M to Push Anti-Tumor Tech Towards Clinic Post author:Sam Post published:December 12, 2017 Post category:BioPharma Pionyr was founded in 2015 by a UCSF professor and a Genentech alum. Source: BioSpace You Might Also Like Almirall Discontinues R&D for Two Drugs in the U.S. September 28, 2017 Hebron Technology Co. Signs Framework Agreement To Form JV With Ukrainian Company June 25, 2017 Genomics Startup Emerges From Stealth Mode By Leading Harvard Geneticist February 8, 2018
